Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deathsPaul Bastard, Luisa Imberti, Adrian Gervais et al.|Science Immunology|2021Cited by 638
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Luisa Imberti, Paul Bastard et al.|Proceedings of the National Academy of Sciences|2022Cited by 198
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunityMaria Elena Maccari, Christian Klemann, Federica Barzaghi et al.|Journal of Allergy and Clinical Immunology|2023Cited by 74
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in childrenPaul Bastard, Carolina Prando, Adrian Gervais et al.|The Journal of Experimental Medicine|2024Cited by 43
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJérémy Manry, Luisa Imberti, Paul Bastard et al.|Research Square|2022Cited by 24